162 related articles for article (PubMed ID: 18045828)
1. Is PTH a risk factor for cardiovascular calcifications in haemodialysis?
Cozzolino M; Brancaccio D
Nephrol Dial Transplant; 2008 Mar; 23(3):1067-8; author reply 1068-9. PubMed ID: 18045828
[No Abstract] [Full Text] [Related]
2. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment.
Barna I; Váradi A; Lakatos P
J Intern Med; 1999 Mar; 245(3):311-3. PubMed ID: 10205596
[No Abstract] [Full Text] [Related]
3. How abnormal calcium, phosphate, and parathyroid hormone relate to cardiovascular disease.
Bro S
Nephrol Nurs J; 2003 Jun; 30(3):275-81; quiz 282-3. PubMed ID: 12861895
[TBL] [Abstract][Full Text] [Related]
4. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients.
Matias PJ; Ferreira C; Jorge C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Nephrol Dial Transplant; 2009 Feb; 24(2):611-8. PubMed ID: 18775809
[TBL] [Abstract][Full Text] [Related]
5. [Diffuse pulmonary calcifications caused by hyperparathyroidism in a renal transplant recipient].
Langenegger T; Diener PA; Diethelm M
Dtsch Med Wochenschr; 2007 Feb; 132(8):375-8. PubMed ID: 17299676
[TBL] [Abstract][Full Text] [Related]
6. Metastatic pulmonary calcifications in severe secondary hyperparathyroidism: evolution after renal transplantation.
Fulladosa X; González MT; Cruzado JM; Andrés E; Castelao AM; Griñó JM; Alsina J
Transplant Proc; 1995 Aug; 27(4):2272-6. PubMed ID: 7652803
[No Abstract] [Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.
Brunaud L; Germain A; Zarnegar R; Rancier M; Alrasheedi S; Caillard C; Ayav A; Weryha G; Mirallie E; Bresler L
Surgery; 2009 Dec; 146(6):1035-41. PubMed ID: 19958930
[TBL] [Abstract][Full Text] [Related]
9. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality.
Schmitt CP; Odenwald T; Ritz E
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S78-80. PubMed ID: 16565253
[TBL] [Abstract][Full Text] [Related]
10. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
11. [Role of vitamin D and its analogues in dialysis patients: beyond PTH control].
Cozzolino M
G Ital Nefrol; 2007; 24(2):107. PubMed ID: 17458822
[No Abstract] [Full Text] [Related]
12. [Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis].
Goicoechea MA
Nefrologia; 2004; 24 Suppl(6):142-60, 187-235. PubMed ID: 15696904
[No Abstract] [Full Text] [Related]
13. Radioimmunoassay of human parathyroid hormone. A review with special reference to hyperparathyroidism in renal disease.
Christensen MS
Dan Med Bull; 1979 Jul; 26(4):157-74. PubMed ID: 385252
[No Abstract] [Full Text] [Related]
14. [Vascular calcifications in patients with uremia: the hypothesis of the three ''culprits''].
Cozzolino M
G Ital Nefrol; 2009; 26(5):562. PubMed ID: 19802801
[No Abstract] [Full Text] [Related]
15. [Long-term persistent hypocalcemia in a hemodialysis patient-- pathogenesis of secondary hyperparathyroidism].
Kitoh C; Kurauchi K; Fujiwara R
Nihon Jinzo Gakkai Shi; 1983 Aug; 25(8):1011-6. PubMed ID: 6668742
[No Abstract] [Full Text] [Related]
16. Taking aim at targets.
Palmer SC; Craig JC; Strippoli GF
Nephrol Dial Transplant; 2009 May; 24(5):1358-61. PubMed ID: 19211650
[No Abstract] [Full Text] [Related]
17. Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis.
Shahapuni I; Esper NE; Opisiv R; Massy Z; Choukroun G; Garabedian M; Fournier A
Nephrol Dial Transplant; 2008 Apr; 23(4):1456-7; author reply 1457-8. PubMed ID: 18039645
[No Abstract] [Full Text] [Related]
18. [Cardiovascular risk in women with chronic renal failure: mammographic study of vascular calcifications].
Canabal A; Sabate J; Salgueira M; Palma A
Radiologia; 2008; 50(1):54-60. PubMed ID: 18275790
[TBL] [Abstract][Full Text] [Related]
19. [Diffuse bronchial calcinosis revealing latent primary hyperparathyroidism].
Wipf R; Stinghe R
Poumon Coeur; 1976; 32(5):251-5. PubMed ID: 826896
[TBL] [Abstract][Full Text] [Related]
20. [Changes in the pre-transplant bone-mineral metabolism do not affect the initial progress of the renal graft].
Rodrigo Calabia E; Ruiz San Millán JC; Gago M; Ruiz Criado J; Piñera Haces C; Fernández Fresnedo G; Palomar R; Gómez Alamillo C; Martín de Francisco AL; Arias M
Nefrologia; 2009; 29(2):143-9. PubMed ID: 19396320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
